论文部分内容阅读
目的探讨门冬氨酸钾镁联合胺碘酮对急性心肌梗死并发室性心律失常的疗效和安全性。方法选取2015年2月-2016年3月本院收治急性心肌梗死并发室性心律失常患者94例,随机分为观察组和对照组各47例。对照组患者给予胺碘酮治疗,观察组患者在对照组基础上加用门冬氨酸钾镁治疗,对比两组治疗效果及用药安全性。结果观察组总有效率为95.74%(45/47),显著高于对照组的80.85%(38/47),差异有统计学意义(P<0.05)。两组皮疹、房室传导阻滞及其他不良反应发生率对比,差异均无统计学意义(均P>0.05)。结论门冬氨酸钾镁联合胺碘酮对急性心肌梗死并发室性心律失常患者疗效显著,安全性较好。
Objective To investigate the efficacy and safety of potassium-magnesium aspartate combined with amiodarone on ventricular arrhythmias in patients with acute myocardial infarction. Methods From February 2015 to March 2016, 94 patients with acute myocardial infarction complicated with ventricular arrhythmias admitted to our hospital were randomly divided into observation group and control group, 47 cases each. Patients in the control group were treated with amiodarone. Patients in the observation group were treated with potassium-magnesium aspartate on the basis of the control group, and the treatment effect and medication safety were compared between the two groups. Results The total effective rate in the observation group was 95.74% (45/47), which was significantly higher than that in the control group (80.85%, 38/47). The difference was statistically significant (P <0.05). There was no significant difference in the incidence of rash, atrioventricular block and other adverse reactions between the two groups (all P> 0.05). Conclusion Aspartate, potassium and magnesium combined with amiodarone have a significant effect on patients with acute myocardial infarction complicated by ventricular arrhythmias, and are safe.